Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paracetamol intravenous - Bristol-Myers Squibb/Mallinckrodt

Drug Profile

Paracetamol intravenous - Bristol-Myers Squibb/Mallinckrodt

Alternative Names: Acelio; acetaminophen IV; Acetavance; IV APAP; Ofirmev; Perfalgan; TRM-1106

Latest Information Update: 02 Jun 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmatop
  • Developer Bristol-Myers Squibb; Mallinckrodt plc; Terumo
  • Class Acetanilides; Aminophenols; Antipyretics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever; Pain

Most Recent Events

  • 02 Jun 2017 No recent reports on development identified - Registered for Fever and Pain in Canada (IV)
  • 18 Nov 2016 Mallinckrodt Pharmaceuticals completes a Pharmacokinetics trial in United Kingdom
  • 08 Nov 2016 The US FDA approved a Prior Approval Supplement for acetaminophen injection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top